Mutant HRAS as novel target for MEK and mTOR inhibitors
Michael K. Kießling(German Cancer Research Center), Gerhard Rogler(University Hospital of Zurich)
Cited by 59
Related Papers
Extraintestinal Manifestations of Inflammatory Bowel Disease
|Inflammatory Bowel Diseases|2015|891
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management
|Gastroenterology|2021|821
Microbial network disturbances in relapsing refractory Crohn’s disease
|Nature Medicine|2019|452
Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome
|Gut|2016|318
European society of neurogastroenterology and motility guidelines on functional constipation in adults
|Neurogastroenterology & Motility|2019|233